EYEG - EyeGate Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.53
+0.00 (+0.94%)
As of 9:42AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.52
Open0.52
Bid0.51 x 4000
Ask0.53 x 1300
Day's Range0.51 - 0.53
52 Week Range0.29 - 1.38
Volume12,275
Avg. Volume525,659
Market Cap22.936M
Beta3.20
PE Ratio (TTM)N/A
EPS (TTM)-0.54
Earnings DateMay 7, 2018 - May 11, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • GlobeNewswire7 days ago

    EyeGate Pharmaceuticals Announces New Board Member, Peter Greenleaf

    EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced the appointment of Peter Greenleaf to its Board of Directors. Mr. Greenleaf was elected to the Board at the Company’s annual stockholders meeting on July 10, 2018. Paul Chaney, EyeGate’s Chairman, said, “We are pleased to welcome Peter Greenleaf to the EyeGate Board.

  • GlobeNewswire11 days ago

    EyeGate Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update

    EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or “the Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced financial results for the three month period ended June 30, 2018, and provided an update on recent corporate and operational activities. Stephen From, EyeGate’s Chief Executive Officer, said, “We continue to hit operational milestones, which culminated with the FDA’s approval of our two IDE submissions, allowing us to move forward with clinical trials for the EyeGate Ocular Bandage Gel in two indications.” Mr. From continued, “Additionally, we added two new Board members, who each bring a wealth of biopharmaceutical experience to EyeGate.

  • Zacks Small Cap Research19 days ago

    EYEG: IDEs Approved. Both OBG Clinical Studies Set to Kick-Off

    As we noted in our Q1 ’18 earnings update in late-May, Eyegate Pharmaceuticals' (EYEG) diligence in rapidly responding to FDAs follow-on questions related to their IDE submission has been key to keeping their Ocular Bandage Gel (OBG) programs on-track with updated forecasted timelines. EYEG had previously been guiding for commencement of both studies during Q3 (i.e.

  • EyeGate Pharmaceuticals Stock Rose ~5.8% on July 24
    Market Realist20 days ago

    EyeGate Pharmaceuticals Stock Rose ~5.8% on July 24

    On July 24, EyeGate Pharmaceuticals (EYEG) announced that it has secured FDA approval for two investigational device exemption applications related to pilot studies for the company’s OBG (ocular bandage gel) product scheduled to commence in the third quarter. In one pivotal study, the company will compare the OBG (or CHMA-S) product with the combination of bandage contact lens and artificial tears, which is the current standard of care for patients who have undergone photorefractive keratectom and require accelerated re-epithelialization of the corneal wounds.

  • GlobeNewswire21 days ago

    EyeGate Announces FDA Approval of Two IDE Submissions for Ocular Bandage Gel

    EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced the U.S. Food and Drug Administration (FDA) has approved two of EyeGate’s Investigational Device Exemption (IDE) applications for pilot studies of the company’s Ocular Bandage Gel (OBG) product for the acceleration of re-epithelialization of large corneal epithelial defects in patients having undergone photorefractive keratectomy (PRK), as well as the reduction in corneal staining for patients with punctate epitheliopathies (PE). EyeGate anticipates entering the clinic for both indications in the third quarter of 2018.

  • ACCESSWIRElast month

    Free Pre-Market Technical Pulse on FibroGen and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / July 10, 2018 / If you want a free Stock Review on FGEN sign up now at www.wallstequities.com/registration. Pre-market, WallStEquities.com evaluates EyeGate Pharmaceuticals Inc. (NASDAQ: EYEG), EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT), Fate Therapeutics Inc. (NASDAQ: FATE), and FibroGen Inc. (NASDAQ: FGEN).

  • GlobeNewswire2 months ago

    EyeGate Addresses Final FDA Action Item with Submission of IDE Amendment for Ocular Bandage Gel

    EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced that it has addressed the final action item in the U.S. Food and Drug Administration’s (FDA) review of its Investigational Device Exemption (IDE) for a second pilot study of the Company’s Ocular Bandage Gel (OBG). EyeGate’s product is a cross-linked thiolated carboxymethyl hyaluronic acid (CMHA-S) platform being developed for the acceleration of re-epithelialization of large corneal epithelial defects in patients having undergone photorefractive keratectomy (PRK).

  • ACCESSWIRE2 months ago

    Blog Exposure - FibroGen Completed Enrollment in US Phase-3 Clinical Program for Roxadustat in CKD Associated Anemia

    LONDON, UK / ACCESSWIRE / June 11, 2018 / If you want access to our free research report on FibroGen, Inc. (NASDAQ: FGEN), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=FGEN as the Company's latest news hit the wire. On June 07, 2018, the Company announced that it has completed patient enrollment in the Phase-3 studies supporting the US new drug application (NDA) submission for Roxadustat in anemia associated with chronic kidney disease (CKD).

  • GlobeNewswire2 months ago

    EyeGate Files Supplement to Investigational Device Exemption to Commence Study in Punctate Epitheliopathy using the EyeGate Ocular Bandage Gel

    EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced the filing of an Investigational Device Exemption (IDE) supplement for Punctate Epitheliopathy (PE), using the Company’s Ocular Bandage Gel (OBG) product. PE represents an unmet medical need and is an opportunity for EyeGate’s OBG platform to expand to additional indications.

  • Zacks Small Cap Research3 months ago

    EYEG: 3 of 4 FDA Questions Answered, OBG-PRK Study On-Track for Q3 Start

    Through Q1 2018, EYEG collected $12.5M related to upfront payments and development milestones from the two Valeant agreements related to EGP-437 programs in anterior uveitis and post-cataract surgery. While FDA’s requests have resulted in delays in getting the IDE through the approval process, EYEG has been diligent in responding to their questions – which has been key to keeping timelines intact.

  • Want To Invest In EyeGate Pharmaceuticals Inc (NASDAQ:EYEG)? Here’s How It Performed Lately
    Simply Wall St.3 months ago

    Want To Invest In EyeGate Pharmaceuticals Inc (NASDAQ:EYEG)? Here’s How It Performed Lately

    Examining how EyeGate Pharmaceuticals Inc (NASDAQ:EYEG) is performing as a company requires looking at more than just a years’ earnings. Below, I will run you through a simple sense checkRead More...

  • GlobeNewswire3 months ago

    EyeGate Addresses Majority of FDA’s Action Items with Submission of Investigational Device Exemption Amendment for Ocular Bandage Gel

    EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced that it has addressed three of the four outstanding items in a Second Amendment in response to the U.S. Food and Drug Administration’s (FDA) review of its first amendment. EyeGate has demonstrated continued progress towards achieving the Investigational Device Exemption (IDE) for a second pilot study of the Company’s Ocular Bandage Gel (OBG) product, a cross-linked thiolated carboxymethyl hyaluronic acid (CMHA-S) platform being developed for the acceleration of re-epithelialization of large corneal epithelial defects in patients having undergone photorefractive keratectomy (PRK).

  • GlobeNewswire3 months ago

    EyeGate Pharmaceuticals Announces New Board Member, Steven Boyd

    EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced that Steven Boyd has joined its board. Paul Chaney, EyeGate’s Chairman, said, “We are pleased to welcome Steven Boyd to the Board of EyeGate. Mr. Boyd said, “I am excited to join the Board of a company like EyeGate with two unique and proprietary platforms that I strongly believe in.

  • Are Insiders Too Confident In EyeGate Pharmaceuticals Inc (NASDAQ:EYEG)?
    Simply Wall St.3 months ago

    Are Insiders Too Confident In EyeGate Pharmaceuticals Inc (NASDAQ:EYEG)?

    EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye. EyeGate Pharmaceuticals is one of United States’s small-capRead More...

  • EyeGate Pharmaceuticals Inc (NASDAQ:EYEG): Poised For Long-Term Success?
    Simply Wall St.5 months ago

    EyeGate Pharmaceuticals Inc (NASDAQ:EYEG): Poised For Long-Term Success?

    The most recent earnings update EyeGate Pharmaceuticals Inc’s (NASDAQ:EYEG) released in December 2017 confirmed company earnings became less negative compared to the previous year’s level as a result of recentRead More...

  • Zacks Small Cap Research6 months ago

    EYEG: Cataract Surgery Phase II Topline Data: Efficacy Signal Despite Miss to Primary Endpoint

    Earlier this month EyeGate (EYEG) announced top-line results of its phase IIb study evaluating the safety and efficacy of EGP-437 in patients which underwent cataract surgery with implantation of a monofocal posterier chamber intra-ocular lens (IOL).  Primary efficacy endpoint is the proportion of subjects with an anterior chamber (AC) cell count of zero at Day 7 and the proportion of subjects with pain score of zero at Day 1.  Secondary endpoints are change in mean ACC on Day 7 and change in mean pain score on Day 1.